Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A study to compare the pharmacokinetics of 3 types of K-877 controlled release tablets with a current normal K-877 tablet in healthy adult subjects.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Treatment A | Experimental | K-877 CR Tablet A |
|
| Treatment B | Experimental | K-877 CR Tablet B |
|
| Treatment C | Experimental | K-877 CR Tablet E |
|
| Treatment D | Experimental | K-877 IR Tablet |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| K-877 CR Tablet A | Drug | K-877 Controlled Release Tablet A |
|
| Measure | Description | Time Frame |
|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve (AUC) | Up to 24 hours after single administration | |
| Maximum Measured Plasma Concentration (Cmax) | Up to 24 hours after single administration |
| Measure | Description | Time Frame |
|---|---|---|
| Treatment emergent adverse events summarized by treatment | Up to 16 days after administration |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| PPD Development, LP | Austin | Texas | 78744 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| K-877 CR Tablet B | Drug | K-877 Controlled Release Tablet B |
|
| K-877 CR Tablet E | Drug | K-877 Controlled Release Tablet E |
|
| K-877 IR Tablet | Drug | K-877 Immediate Release Tablet |
|